Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug development: Mix and match.

× No keyword cloud information.

5 in total

1. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors: Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal: Mol Ther Date: 2010-02-23 Impact factor: 11.454

2. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

Authors: Maria R Parkhurst; James C Yang; Russell C Langan; Mark E Dudley; Debbie-Ann N Nathan; Steven A Feldman; Jeremy L Davis; Richard A Morgan; Maria J Merino; Richard M Sherry; Marybeth S Hughes; Udai S Kammula; Giao Q Phan; Ramona M Lim; Stephen A Wank; Nicholas P Restifo; Paul F Robbins; Carolyn M Laurencot; Steven A Rosenberg
Journal: Mol Ther Date: 2010-12-14 Impact factor: 11.454

3. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.

Authors: Matthew Witek; Erik S Blomain; Michael S Magee; Bo Xiang; Scott A Waldman; Adam E Snook
Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-01 Impact factor: 7.038

4. Comprehensive molecular characterization of human colon and rectal cancer.

Authors:
Journal: Nature Date: 2012-07-18 Impact factor: 49.962

5. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

Authors: A Johnsson; H Hagman; J-E Frödin; A Berglund; N Keldsen; E Fernebro; J Sundberg; R De Pont Christensen; K-L Garm Spindler; D Bergström; A Jakobsen
Journal: Ann Oncol Date: 2013-06-19 Impact factor: 32.976

5 in total

4 in total

4. Circulating miRNAs as novel diagnostic biomarkers in hepatocellular carcinoma detection: a meta-analysis based on 24 articles.

Authors: Yan Ding; Jia-Lai Yan; An-Ning Fang; Wei-Feng Zhou; Ling Huang
Journal: Oncotarget Date: 2017-07-04

4 in total

Drug development: Mix and match.

1. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

2. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

3. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.

4. Comprehensive molecular characterization of human colon and rectal cancer.

5. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

1. DHX33 Transcriptionally Controls Genes Involved in the Cell Cycle.

2. Targeting colorectal cancer-associated bacteria: A new area of research for personalized treatments.

3. Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review.

4. Circulating miRNAs as novel diagnostic biomarkers in hepatocellular carcinoma detection: a meta-analysis based on 24 articles.